RU2006128293A - Коньюгаты гормона роста человека, монопэгилированного по n-концу, способ их получения и способы их применения - Google Patents

Коньюгаты гормона роста человека, монопэгилированного по n-концу, способ их получения и способы их применения Download PDF

Info

Publication number
RU2006128293A
RU2006128293A RU2006128293/14A RU2006128293A RU2006128293A RU 2006128293 A RU2006128293 A RU 2006128293A RU 2006128293/14 A RU2006128293/14 A RU 2006128293/14A RU 2006128293 A RU2006128293 A RU 2006128293A RU 2006128293 A RU2006128293 A RU 2006128293A
Authority
RU
Russia
Prior art keywords
growth hormone
formula
polyethylene glycol
hgh
human growth
Prior art date
Application number
RU2006128293/14A
Other languages
English (en)
Inventor
Рори Ф. ФИНН (US)
Рори Ф. Финн
Original Assignee
Фармация Корпорейшн (Us)
Фармация Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2006128293(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармация Корпорейшн (Us), Фармация Корпорейшн filed Critical Фармация Корпорейшн (Us)
Publication of RU2006128293A publication Critical patent/RU2006128293A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)

Claims (10)

1. Способ предотвращения и/или лечения заболевания или расстройства, при котором полезно применение гормона роста, включающий введение пациенту, нуждающемуся в этом, терапевтически эффективного количества модифицированного полиэтиленгликолем ГРЧ, который имеет структуру формулы I или II
Figure 00000001
Формула I
или
Figure 00000002
Формула II
где n является целым числом от 1 до 10;
m является целым числом от 1 до 10;
R является гормоном роста человека или метионил-гормоном роста,
одного или в комбинации с другим терапевтическим средством, где указанное заболевание или расстройство, при котором полезно применение гормона роста, выбрано из группы, состоящей из недостаточности гормона роста (GHD), недостаточности гормона роста у взрослых (aGHD), синдрома Тернера; задержки роста у детей, чей рост при рождении был недостаточным для гестационного возраста (SGA); синдрома Прадера-Вилли (PWS), хронической почечной недостаточности (CRI), травматического повреждения головного мозга, субарахноидального кровоизлияния, синдрома Нунан, идиопатической низкорослости (ISS), очень низкой массы при рождении (VLBW), низкорослости у детей вследствия лечения глюкокортикоидами и отсутствия ускорения роста у низкорослых недоношенных детей.
2. Способ по п.1, где указанное заболевание или расстройство, в котором полезно применение ГР, выбрано из группы, состоящей из GHD, aGHD, синдрома Тернера, SGA, PWS, CRI и ISS.
3. Способ по п.1 или 2, где n равно 4, а m равно 3.
4. Способ по п.3, где указанный модифицированный полиэтиленгликолем ГРЧ имеет структуру формулы I, причем n равно 4 и m равно 3.
5. Способ по п.1, где указанный гормон роста человека включает аминокислотную последовательность SEQ ID NO:1.
6. Способ по п.5, где более 90% указанного полиэтиленгликоля конъюгировано с N-концевым фенилаланином аминокислотной последовательности SEQ ID NO:1.
7. Способ по 6, где более 95% указанного полиэтиленгликоля конъюгировано с N-концевым фенилаланином аминокислотной последовательности SEQ ID NO:1.
8. Способ по п.1, где каждый мПЭГ имеет молекулярную массу приблизительно 20 кДа.
9. Композиция, содержащая конъюгат гормона роста человека с с ПЭГ формулы I или II в комбинации с другим терапевтическим средством и по меньшей мере с одним фармацевтически приемлемым носителем
Figure 00000001
Формула I
или
Figure 00000002
Формула II
где n является целым числом от 1 до 10;
m является целым числом от 1 до 10;
R является гормоном роста человека или метионил-гормоном роста.
10. Композиция по п.9, где указанный модифицированный полиэтиленгликолем ГРЧ имеет структуру формулы I, причем n равно 4 и m равно 3.
RU2006128293/14A 2004-02-04 2005-01-24 Коньюгаты гормона роста человека, монопэгилированного по n-концу, способ их получения и способы их применения RU2006128293A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/771,895 2004-02-04
US10/771,895 US20040142870A1 (en) 2002-11-20 2004-02-04 N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

Publications (1)

Publication Number Publication Date
RU2006128293A true RU2006128293A (ru) 2008-02-10

Family

ID=34886516

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006128293/14A RU2006128293A (ru) 2004-02-04 2005-01-24 Коньюгаты гормона роста человека, монопэгилированного по n-концу, способ их получения и способы их применения

Country Status (21)

Country Link
US (1) US20040142870A1 (ru)
EP (2) EP1715887B1 (ru)
JP (3) JP2007520544A (ru)
KR (2) KR100776862B1 (ru)
CN (1) CN1929857A (ru)
AT (1) ATE365047T1 (ru)
AU (1) AU2005215250A1 (ru)
BR (1) BRPI0507427A (ru)
CA (1) CA2555772A1 (ru)
CY (1) CY1106723T1 (ru)
DE (1) DE602005001445T2 (ru)
DK (1) DK1715887T3 (ru)
ES (1) ES2286787T3 (ru)
IL (1) IL176998A0 (ru)
NO (1) NO20063926L (ru)
PL (1) PL1715887T3 (ru)
PT (1) PT1715887E (ru)
RU (1) RU2006128293A (ru)
TW (2) TW200529868A (ru)
WO (1) WO2005079838A1 (ru)
ZA (2) ZA200706349B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
RS20050202A (en) 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
RS20050502A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
WO2006023608A2 (en) * 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
WO2006018428A2 (en) * 2004-08-20 2006-02-23 Novo Nordisk A/S Hemopexin fusion proteins
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2627939A1 (en) * 2005-12-15 2007-06-21 Laboratoires Serono S.A. New chemokine antagonists
US20100016550A1 (en) * 2006-05-26 2010-01-21 Zheng Xin Dong Methods for Site-Specific Pegylation
CA2720306C (en) * 2008-04-03 2016-03-15 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
SI3050576T1 (sl) * 2008-04-29 2021-08-31 Ascendis Pharma Endocrinology Division A/S Spojine pegiliranega rekombinantnega humanega rastnega hormona
EP2313457B1 (en) * 2008-07-31 2020-01-15 PharmaEssentia Corp. Peptide-polymer conjugates
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2011018515A1 (en) * 2009-08-14 2011-02-17 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
WO2011073234A2 (en) 2009-12-15 2011-06-23 Ascendis Pharma As Growth hormone composition
CN102453089B (zh) * 2010-10-25 2014-06-04 北京凯因科技股份有限公司 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
EP2788014B8 (en) * 2011-12-09 2019-10-23 Metabolic Pharmaceuticals Pty Ltd Use of growth hormone fragments
CN102964588A (zh) * 2012-11-09 2013-03-13 河南工业大学 末端连接氨基苯丙酸的聚乙二醇的酸或活性酯的制法和应用
KR101599415B1 (ko) 2015-05-29 2016-03-03 (주)신명이앤씨 건축물 층간 바닥 전기 케이블 보호관
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53104A (en) * 2001-11-20 2006-10-27 Pharmacia Corporation Chemically-modified human growth hormone conjugates
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

Also Published As

Publication number Publication date
BRPI0507427A (pt) 2007-06-26
TW200529868A (en) 2005-09-16
KR20060120240A (ko) 2006-11-24
CA2555772A1 (en) 2005-09-01
JP2008037872A (ja) 2008-02-21
US20040142870A1 (en) 2004-07-22
NO20063926L (no) 2006-10-30
DE602005001445D1 (de) 2007-08-02
ATE365047T1 (de) 2007-07-15
JP2008001713A (ja) 2008-01-10
AU2005215250A1 (en) 2005-09-01
KR100776862B1 (ko) 2007-11-28
PT1715887E (pt) 2007-08-29
TW200812610A (en) 2008-03-16
CN1929857A (zh) 2007-03-14
CY1106723T1 (el) 2012-05-23
ZA200606375B (en) 2007-11-28
PL1715887T3 (pl) 2007-12-31
DE602005001445T2 (de) 2008-02-14
KR20070039623A (ko) 2007-04-12
DK1715887T3 (da) 2007-09-17
WO2005079838A1 (en) 2005-09-01
ES2286787T3 (es) 2007-12-01
JP2007520544A (ja) 2007-07-26
EP1715887B1 (en) 2007-06-20
EP1715887A1 (en) 2006-11-02
IL176998A0 (en) 2006-12-10
ZA200706349B (en) 2008-06-25
EP1915999A1 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
RU2006128293A (ru) Коньюгаты гормона роста человека, монопэгилированного по n-концу, способ их получения и способы их применения
AU2020200626B2 (en) Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment
US10550168B2 (en) Composition for treating diabetes or diabesity comprising oxyntomodulin analog
JP6231522B2 (ja) 免疫グロブリン断片を用いたインスリン薬物結合体
TWI593422B (zh) 新穎之長效升糖素共軛物及包含其用於肥胖預防與治療之醫藥組成物
RU2446816C2 (ru) Фармацевтическая композиция для лечения связанных с ожирением заболеваний, содержащая конъюгат инсулинотропного пептида
TWI666219B (zh) 使用免疫球蛋白片段之位點專一性ｇｌｐ－２接合物
KR101352225B1 (ko) 신규한 엑센딘 변형 및 이들의 콘쥬게이트
ES2715326T3 (es) Formulación liquida de conjugado de insulina de acción prolongada
EP3137103B1 (en) Methods and compositions for modulating the immune system with arginase i
KR20140040164A (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
EP2838552A1 (en) Long-acting oxyntomodulin variants and methods of producing same
TW201004649A (en) A polypeptide complex comprising non-peptidyl polymer having three functional ends
WO2008136611A1 (en) Natriuretic peptide conjugate using carrier substance
US20230248836A1 (en) Dosage Regimen for a Controlled-Release PTH Compound
KR102185311B1 (ko) 인슐린 위치 특이적 결합체
KR20110134210A (ko) 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
JP2002502369A (ja) 胃腸管上部の機能を強化する方法
US20230159607A1 (en) Pharmaceutical composition for preventing or treating mucositis induced by radiotherapy, chemotherapy, or combination thereof, comprising glp-2 derivatives or long-acting conjugate of same
RU2010136327A (ru) Гормон роста, модифицированный двухцепочечным полиэтиленгликолем, его способ получения и применение
KR101746686B1 (ko) 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체
JP2009502779A (ja) 生体適合性ポリマーに結合させたヒト成長ホルモン
JP2009502779A5 (ru)
JP2014516985A (ja) 非ペプチド性重合体−インスリン多量体及びその製造方法
US20060134736A1 (en) Human growth hormone conjugated with biocompatible polymer

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20080922

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20080922

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20080922